Language:

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

The New England journal of medicine, 2015-07, Vol.373 (3), p.232-242 [Peer Reviewed Journal]

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1501352 ;PMID: 26052984

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Author: Green, Jennifer B ; Bethel, M. Angelyn ; Armstrong, Paul W ; Buse, John B ; Engel, Samuel S ; Garg, Jyotsna ; Josse, Robert ; Kaufman, Keith D ; Koglin, Joerg ; Korn, Scott ; Lachin, John M ; McGuire, Darren K ; Pencina, Michael J ; Standl, Eberhard ; Stein, Peter P ; Suryawanshi, Shailaja ; Van de Werf, Frans ; Peterson, Eric D ; Holman, Rury R
Subjects: Administration, Oral ; Angina ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - mortality ; Care and treatment ; Cerebral infarction ; Clinical trials ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-peptidase IV ; Dosage and administration ; Double-Blind Method ; Drug therapy ; Drug Therapy, Combination ; Follow-Up Studies ; Glycated Hemoglobin A - analysis ; Health risk assessment ; Heart diseases ; Heart Diseases - epidemiology ; Heart Diseases - etiology ; Heart Failure - etiology ; Hemoglobin ; Hospitalization - statistics & numerical data ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Influence ; Inhibitor drugs ; Kaplan-Meier Estimate ; Myocardial infarction ; Pancreatic cancer ; Pancreatitis ; Peptidase ; Pyrazines - adverse effects ; Pyrazines - therapeutic use ; Side effects ; Sitagliptin ; Sitagliptin Phosphate ; Stroke ; Triazoles - adverse effects ; Triazoles - therapeutic use ; Type 2 diabetes
Is Part Of: The New England journal of medicine, 2015-07, Vol.373 (3), p.232-242
Description: The addition of sitagliptin to usual care in patients with type 2 diabetes and cardiovascular disease was not associated with any change in the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. Good glycemic control among patients with type 2 diabetes reduces the risk of diabetes-related microvascular complications. 1 – 3 Many antihyperglycemic agents are licensed for the treatment of type 2 diabetes, but questions regarding the long-term cardiovascular safety of some of these agents have been raised. 4 , 5 International regulatory agencies have responded by requiring that new antihyperglycemic agents not only show glucose-lowering ability but also are not associated with clinically meaningful increases in rates of major adverse cardiovascular events. 6 , 7 Sitagliptin, an orally administered dipeptidyl peptidase 4 (DPP-4) inhibitor, prolongs the action of incretin hormones, including glucagon-like peptide 1 and glucose-dependent insulinotropic . . .
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1501352
PMID: 26052984
Source: ProQuest One Psychology
MEDLINE
Alma/SFX Local Collection
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1501352 ;PMID: 26052984

Searching Remote Databases, Please Wait